• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Phibro Animal Health Corporation

    2/8/24 11:38:01 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PAHC alert in real time by email
    SC 13G 1 phibro_animal_hea_13g_de.htm SC 13G SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    Phibro Animal Health Corp

    (Name of Issuer)

    COMMON STOCK

    (Title of Class of Securities)

    71742Q106

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    ☒ Rule 13d-1(b)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     

     

     

    SCHEDULE 13G

     

     

    CUSIP NO. 71742Q106

     

     

     

    PAGE 2 OF 6 PAGES

     

    1.

    Name of reporting person/s.s. Or I.R.S. Identification

    No. of above person

     

    PZENA INVESTMENT MANAGEMENT, LLC

    2.

    Check the appropriate box if a member of a group

    (a) ☐    (b) ☐

    3.

    SEC use only

     

    4.

    Citizenship or place of organization

    DELAWARE

    Number of

    5.

    Sole voting power

    1,663,664

    shares

    beneficially

    owned by

    6.

    Shared voting power

    0

    each

    reporting

    person

    7.

    Sole dispositive power

       1,989,558

    with:

    8.

    Shared dispositive power

    0

    9.

    Aggregate amount beneficially owned by each reporting person

    1,989,558

    10.

    Check box if the aggregate amount in Row (9) excludes certain shares*

    ☐

     

    11.

    Percent of class represented by amount in Row (9)

       9.8%

    12.

    Type of reporting person*

    IA

     

     

     


     

     

     

    SCHEDULE 13G

     

     

    CUSIP NO. 71742Q106

     

     

     

    PAGE 3 OF 6 PAGES

     

    ITEM 1.

    (a) Name of Issuer: Phibro Animal Health Corp

    (b) Address of Issuer's Principal Executive Offices:

    Glenpointe Centre East, 3rd Floor

    300 Frank W. Burr Blvd, Suite 21, Teaneck, NJ 07666

    ITEM 2.

    (a) Name of Person Filing: Pzena Investment Management, LLC

    (b) Address of Principal Business Office or, if none, Residence:

    320 Park Avenue, 8th Floor, New York, NY 10022

    (c) Citizenship: Delaware

    (d) Title of Class of Securities: Common Stock

    (e) CUSIP Number: 71742Q106

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B), CHECK WHETHER THE PERSON FILING IS A:

     

    (a)

     

    [ ]

     

    Broker or Dealer registered under Section 15 of the Act

    (b)

     

    [ ]

     

    Bank as defined in section 3(a)(6) of the Act

    (c)

     

    [ ]

     

    Insurance Company as defined in section 3(a)(19) of the Act

    (d)

     

    [ ]

     

    Investment Company registered under section 8 of the Investment Company Act of 1940

    (e)

     

    [ x ]

     

    Investment Adviser registered under section 203 of the Investment Advisers Act or under the laws of any State

    (f)

     

    [ ]

     

    Employee Benefit Plan, Pension fund which is subject to the Endowment Fund; see ss.240.13d-1(b)(1)(ii)(F)

    (g)

     

    [ ]

     

    Parent Holding Company or Control Person, in accordance with ss.240.13d-1(b)(ii)(G) (Note: See Item 7)

    (h)

     

    [ ]

     

    A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act

    (i)

     

    [ ]

     

    A Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940

    (j)

     

    [ ]

     

    Group, in accordance with ss.240.13d-1(b)(1)(ii)(J)

    If this statement is filed pursuant to ss.240.13d-1(c), check this box [ ].

     

     


     

     

     

    SCHEDULE 13G

     

     

    CUSIP NO. 71742Q106

     

     

     

    PAGE 4 OF 6 PAGES

     

    ITEM 4. OWNERSHIP

    If the percent of the class owned, as of December 31 of the year covered by this statement, or as of the last day of any month described in Rule 13d-1(b)(2) if applicable exceeds five percent, provide the following information as of that date and identify those shares which there is a right to acquire.

     

    (a)

    Amount Beneficially Owned:

     

    1,989,558

     

     

     

     

    (b)

    Percent of Class:

     

     9.8%

     

     

     

     

    (c)

    Number of shares as to which such person has:

     

     

     

     

     

     

     

    (i)

    sole power to vote or to direct the vote:

     

    1,663,664

     

     

     

     

     

     

    (ii)

    shared power to vote or to direct the vote:

     

    0

     

     

     

     

     

     

    (iii)

    sole power to dispose or to direct the disposition of:

     

      1,989,558

     

     

     

     

     

     

    (iv)

    shared power to dispose or to direct the disposition of:

     

    0

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employees benefit plan, pension fund or endowment fund is not required.

    CLIENTS OF THE FILING INVESTMENT MANAGER HAVE THE RIGHT TO RECEIVE AND THE ULTIMATE POWER TO DIRECT THE RECEIPT OF DIVIDENDS FROM, OR THE PROCEEDS OF SALE OF THE SECURITIES REPORTED ON HEREINABOVE. NO INTEREST OF ANY ONE OF SUCH CLIENTS RELATES TO MORE THAN FIVE PERCENT OF THE CLASS.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c), attach an exhibit stating the identification of the relevant subsidiary. NOT APPLICABLE.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

    If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(h) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. NOT APPLICABLE.

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security report on will be filed, if required, by members of the group, in their individual capacity. NOT APPLICABLE.

     


     

     

     

    SCHEDULE 13G

     

     

    CUSIP NO. 71742Q106

     

     

     

    PAGE 5 OF 6 PAGES

     

     

    ITEM 10. CERTIFICATION

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     


     

     

     

    SCHEDULE 13G

     

     

    CUSIP NO. 71742Q106

     

     

     

    PAGE 6 OF 6 PAGES

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

     

    February 8, 2024

     

     

    /s/ Steven Coffey, Chief Legal Risk Officer & Chief Compliance Officer

    NAME/TITLE

     

     


    Get the next $PAHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAHC

    DatePrice TargetRatingAnalyst
    7/7/2025$35.00Neutral → Overweight
    Analyst
    6/16/2025$24.00Underperform → Neutral
    BNP Paribas Exane
    9/10/2024$22.00Neutral
    JP Morgan
    12/7/2023$9.00Underperform
    Exane BNP Paribas
    12/21/2022$18.00Buy
    ROTH Capital
    7/25/2022$22.00Equal Weight → Underweight
    Barclays
    1/10/2022$23.00Underweight → Equal-Weight
    Barclays
    11/18/2021$23.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $PAHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs

    Phibro Animal Health Corporation (NASDAQ:PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals. This agreement grants Phibro exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma's proprietary compound for canine periodontal care. The compound represents a promising advancement in veterinary dental health, addressing a widespread and often under-treated condition in dogs. "We are excited to partner with Lighthouse Pharma to help develop and commercialize a new solution for periodontal dise

    10/9/25 4:30:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference

    Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. W

    9/2/25 4:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million Diluted earnings per share of $0.42, an increase of $0.40 Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49% Adjusted net income of $23.2 million, an increase of $6.6 million, or 39% Adjusted

    8/27/25 4:57:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Phibro Animal Health Corporation

    DEFA14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    9/19/25 4:15:06 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Phibro Animal Health Corporation

    DEF 14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    9/19/25 4:10:42 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    8/27/25 5:08:02 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bendheim Jack sold $834,412 worth of shares (20,664 units at $40.38) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    10/1/25 4:10:25 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack sold $282,732 worth of shares (7,022 units at $40.26) and converted options into 30,000 shares (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/22/25 6:32:03 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack sold $857,313 worth of shares (21,120 units at $40.59) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/11/25 8:56:36 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corcoran E Thomas bought $110,500 worth of shares (5,000 units at $22.10), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/26/25 4:15:17 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/6/24 4:34:30 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phibro Animal Health upgraded by Analyst with a new price target

    Analyst upgraded Phibro Animal Health from Neutral to Overweight and set a new price target of $35.00

    7/7/25 8:10:48 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Phibro Animal Health from Underperform to Neutral and set a new price target of $24.00

    6/16/25 8:16:19 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Phibro Animal Health with a new price target

    JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00

    9/10/24 7:55:45 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Leadership Updates

    Live Leadership Updates

    View All

    Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.

    1/23/25 4:45:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TerraCycle Appoints New Chief Financial Officer to Global Leadership Team

    Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ --­ TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at

    9/6/23 12:20:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Announces the Appointment of Alejandro Bernal to Its Board of Directors and Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and

    2/6/23 4:15:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Financials

    Live finance-specific insights

    View All

    Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million Diluted earnings per share of $0.42, an increase of $0.40 Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49% Adjusted net income of $23.2 million, an increase of $6.6 million, or 39% Adjusted

    8/27/25 4:57:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results

    Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its fourth quarter and fiscal year 2025 financial results on Wednesday, August 27, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 28, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of

    8/20/25 4:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 24, 2025, to stockholders of record at the close of business on September 3, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please v

    7/29/25 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

    SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/15/24 4:15:40 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/14/24 12:51:31 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/12/24 4:55:22 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care